• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    12/3/25 7:58:54 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email
    6-K 1 pavs_6k.htm FORM 6-K pavs_6k.htm

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2025

     

    PARANOVUS ENTERTAINMENT TECHNOLOGY LIMITED

    (Exact name of registrant as specified in its charter)

     

    250 Park Avenue, 7th Floor

    New York, NY 10017

    929-215-4832

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form40-F.

     

    Form 20-F  ☒      Form 40-F  ☐

     

     

     

     

    Submission of Matters to a Vote of Security Holders.

     

    Paranovus Entertainment Technology Limited (the “Company”) held an extraordinary meeting of shareholders (“EGM”) at 10:00 a.m. EDT on November 26, 2025 at its principal executive offices in 250 Park Avenue, 7th Floor, New York, NY 10017. Shareholders of Class A and Class B ordinary shares voted by proxy or at the meeting. There were shareholders of 75.85% out of a total votes of 66,724,675 Class A ordinary shares (representing 66,724,675 votes) and 612,255 Class B ordinary shares (representing 12,245,100 votes) and therefore constituting a quorum of more than one third of the shares outstanding and entitled to vote at the meeting as of the record date of November 7, 2025. Each Class A ordinary share is entitled to one vote, and each Class B ordinary share is entitled to twenty (20) votes. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

     

    1.

    that the following constitutes the number of shares voted with respect to the special resolution of the shareholders to approve, subject to approval by the shareholders of Class B ordinary shares pursuant to the existing fifth amended and restated memorandum and articles of association of the Company (the “Fifth M&A”), to approve and adopt the sixth amended and restated memorandum and articles of association (the “Sixth M&A”) in the form as attached thereto the meeting notice as Appendix A to reflect, inter alia, the increase of the voting rights attached to each Class B ordinary share of the Company from twenty (20) votes to eighty (80) votes on any and all matters on a poll at any general meeting of the Company (the “Change of Voting Power”), in substitution for the Fifth M&A (the “Amendment to the Fifth M&A” and such proposal, the “Amended M&A Proposal”);

     

    For

     

    Against

     

    Abstain

    87,698,305

    66,343

    4,195

     

     

    Accordingly, the Amended M&A Proposal has been approved, subject to approval by the shareholders of Class B ordinary shares pursuant to the Fifth M&A.

     

     

    2.

    That the following constitutes the votes with respect to the ordinary resolution of the shareholders to approve:

     

     

    (a)

    that the Company effect one or more reverse share splits of its authorized, issued and outstanding share capital by way of consolidation at an exchange ratio of up to one-for-five thousand (1:5,000) in the aggregate (the “Share Consolidations”), such that the number of authorized, issued and outstanding shares is decreased by the applicable ratio and the par value of each authorized, issued and outstanding ordinary share is increased by the same ratio, as applicable, with each Share Consolidation to be effected at such time or times, and at a precise consolidation ratio or ratios, in each case as determined by the board of directors (the “Board”) in its absolute discretion within two (2) years following the date of the EGM, provided that the cumulative consolidation ratio for all such Share Consolidations shall not exceed 1:5,000 in the aggregate (the “Consolidation Ratio Cap”) (the “Share Consolidation Proposal”).

     

     

     

     

    (b)

    no fractional ordinary shares of the Company be issued in connection with each of the Share Consolidations; if a shareholder is entitled to receive a fractional ordinary share upon a Share Consolidation, the total number of ordinary shares to be received by such shareholder be rounded up to the next whole ordinary shares.

     

     

     

     

    (c)

    the Board be authorized, at its absolute and sole discretion, to either (i) implement one or more Share Consolidations, and determine, at any time within two (2) years following the date of the EGM and subject to the Consolidation Ratio Cap, the exact consolidation ratio and effective date of each such Share Consolidation; or (ii) elect not to implement any Share Consolidation during a period of two years of the date of the EGM.

     

     

     

     

    (d)

    if and when deemed advisable by the Board in its sole discretion, any director or officer of the Company be authorized, for and on behalf of the company, to do all such other acts and things and execute all such documents necessary or desirable to implement the Share Consolidation(s).

       

     

    2

     

     

    For

     

    Against

     

    Abstain

    87,686,741

    80,962

    1,140

     

    Accordingly, the Share Consolidation Proposal has been approved. 

        

    3.

    that the following constitutes the number of shares voted with respect to the ordinary resolution of the shareholders to approve, that conditional upon the determination of the exact consolidation ratio and immediately following the first Share Consolidation, the authorized share capital of the Company to be increased FROM USD 5,000,000, TO such amount , within the range between $63,500,000,000 and $167,496,500,000, as results from the creation of an additional number of Class A ordinary shares, in amount within the range between 3,175,000,000 Class A ordinary shares and 3,349,930,000 Class A ordinary shares, such that there shall be a total of 3,350,000,000 Class A ordinary shares in the Company’s authorized share capital, each with a par value equal to that applicable upon effectiveness of the first Share Consolidation (the “First Post-Consolidation Par Value”) and that following such share capital increase, the authorized share capital of the Company shall be divided into (i) 3,350,000,000 Class A ordinary shares, (ii) such number of Class B ordinary shares in the authorized share capital resulting from the first Share Consolidation, and (iii) such number of preferred shares in the authorized share capital resulting from the first Share Consolidation, each with the First Post-Consolidation Par Value (the “Increase of Authorized Share Capital” and such proposal, the “Increase of Authorized Share Capital Proposal”):

     

    For

     

    Against

     

    Abstain

    87,691,470

     

    77,278

     

    95

     

    Accordingly, the Increase of Authorized Share Capital Proposal has been approved.  

      

    Immediately following the EGM, the Company held an extraordinary meeting of shareholders of Class B ordinary shares (“Class B EGM”) at 10:30 a.m. EDT on November 26, 2025 at its principal executive offices in 250 Park Avenue, 7th Floor, New York, NY 10017. Shareholders of Class B ordinary shares voted by proxy or at the meeting. There were shareholders of 100% out of a total votes of 612,255 Class B ordinary shares (representing 12,245,100 votes) and therefore constituting a quorum of more than one third of the shares outstanding and entitled to vote at the meeting as of the record date of November 21, 2025. Each Class B ordinary share is entitled to twenty (20) votes. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

     

    that the following constitutes the number of shares voted with respect to the special resolution, to approve and adopt the Sixth M&A in the form as attached thereto the meeting notice as Appendix A to reflect, inter alia, the Change of Voting Power, in substitution for the Fifth M&A (the Amended M&A Proposal)

     

    For

     

    Against

     

    Abstain

    12,245,100

     

    0

     

    0

     

    Accordingly, the Amended M&A Proposal has been approved.

     

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Paranovus Entertainment Technology Limited

     

     

     

     

     

    Date: December 3, 2025

    By:

    /s/ Xiaoyue Zhang

     

     

     

    Xiaoyue Zhang

    Chief Executive Officer

     

     

     

    4

     

    Get the next $PAVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    SEC Filings

    View All

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    12/5/25 8:31:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by Paranovus Entertainment Technology Ltd.

    EFFECT - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    12/4/25 12:15:29 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    12/3/25 7:58:54 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Turnarounds and 18,000% Growth

    DENVER, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Markets opened the week with a burst of small-cap energy as several niche innovators, spanning luxury foods, next-gen biomaterials, and RNA therapeutics, delivered updates that injected fresh optimism into the narrative before the opening bell: Top Wealth Group (NASDAQ:TWG) Signals a Turnaround Year Top Wealth Group, the premium caviar and fine-wine supplier, set an upbeat tone after projecting no less than $4 million in net profit for FY2025, marking a powerful reversal from last year's $2 million loss. Management attributed the rebound to operational improvements realized throughout 2024. CEO Kim Kwan Kings, Wong said, "We have worked diligent

    12/8/25 9:43:58 AM ET
    $PAVS
    $TWG
    $WVE
    Medicinal Chemicals and Botanical Products
    Health Care
    Packaged Foods
    Consumer Staples

    PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("the Company"), listed on Nasdaq, today announced its financial results for the six months ended September 30, 2025, achieving substantial revenue increase and a meaningful improvement in gross profit following its strategic transformation and acquisition-led growth strategy. The Company reported: Total revenue of $12,413,039 for the six months ended September 30, 2025, compared to $68,454 in the prior-year period, representing ~18,037% year-over-year growth.Net profit attributable to the Compan

    12/5/25 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces Receipt of a Bid Deficiency Notice from Nasdaq

    NEW YORK, July 15, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that on July 11, 2025, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq"), notifying the Company that the minimum bid price per share for its Class A ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's Class A ordinary shares on Nasdaq. Under the

    7/15/25 4:15:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("the Company"), listed on Nasdaq, today announced its financial results for the six months ended September 30, 2025, achieving substantial revenue increase and a meaningful improvement in gross profit following its strategic transformation and acquisition-led growth strategy. The Company reported: Total revenue of $12,413,039 for the six months ended September 30, 2025, compared to $68,454 in the prior-year period, representing ~18,037% year-over-year growth.Net profit attributable to the Compan

    12/5/25 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces Receipt of a Bid Deficiency Notice from Nasdaq

    NEW YORK, July 15, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that on July 11, 2025, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq"), notifying the Company that the minimum bid price per share for its Class A ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's Class A ordinary shares on Nasdaq. Under the

    7/15/25 4:15:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Periodic Financial Reports Filing Rule

    NEW YORK, April 29, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that it has received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq"), dated April 25, 2025, notifying that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(2) (the "Rule"). The Nasdaq staff has determined that the Company complies with the Rule based on the Form 6-K furnished by the Company on April 24, 2025, disclosing its interim financial statements for the six-month ended September 30, 2024. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5250(c)(2) and this filing delinquency matter i

    4/29/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care